Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

Hepatology Research

Volumn 40, Issue 6, 2010, Pages 566-573

  Yoneda, Masato ^a   Fujita, Koji ^a   Nozaki, Yuichi ^a   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Hosono, Kunihiro ^a   Suzuki, Kaori ^a   Mawatari, Hironori ^a   Kirikoshi, Hiroyuki ^a   Inamori, Masahiko ^a   Saito, Satoru ^a   Iwasaki, Tomoyuki ^a   Terauchi, Yasuo ^a   Kubota, Kensuke ^a   Maeyama, Shiro ^b   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kitakashiwa Rehabilitation Hospital   (Japan)

Author keywords

Ezetimibe; NAS score; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

EID: 77954366025     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00644.x     Document Type: Article

References (31)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-31.
2. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterol 2002, 123:1705-25.
3. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988, 95:1056-62.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1985, 55:434-8.
5. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
6. Bellentani S, Saccoccio G, Masutti F. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-7.
7. Saibara T. Nonalcoholic steatohepatitis in Asia-Oceania. Hepatol Res 2005, 33:64-7.
8. Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res 2005, 33:77-82.
9. Chitturi S, Abeygunasekera S, Farrell GC. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-9.
10. Marchesini G, Brizi M, Bianchi G. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-50.
11. Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 2003, 18:1115-7.
12. Marchesini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-23.
13. Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006, 23:207-15.
14. Yokohama S, Yoneda M, Haneda M. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-5.
15. Grundy SM. Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 1983, 3:71-96.
16. Altmann SW, Davis HR, Zhu LJ. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-4.
17. Garcia-Calvo M, Lisnock J, Bull HG. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005, 102:8132-7.
18. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006, 26:2433-8.
19. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:2032-8.
20. Deushi M, Nomura M, Kawakami A. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-70.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-9.
22. Yoshizumi T, Nakamura T, Yamane M. Abdominal fat: standardized technique for measurement at CT. Radiology 1999, 211:283-6.
23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
24. Yoneda M, Mawatari H, Fujita K. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-82.
25. Kleiner DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-21. Nonalcoholic Steatohepatitis Clinical Research Network
26. Beltroy EP, Liu B, Dietschy JM, Turley SD. Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease. J Lipid Res 2007, 48:869-81.
27. Temel RE, Tang W, Ma Y. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007, 117:1968-78.
28. Nozaki Y, Fujita K, Yoneda M. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009, 51:548-56.
29. Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 2002, 30:1091-5.
30. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 1995, 92:935-8.
31. Hughes EA, Tracey I, Singhal S, Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med Hypotheses 2006, 67:1463-4.